Phlexglobal completes management buyout

Phlexglobal is a specialist global contract research organisation (CRO), delivers clinical research support solutions to meet its clients’ needs through its five core services of resourcing, task force, clinical support services, eTMF & document solutions and training.

The deal will allow Phlexglobal to further expand its provision of clinical trial support, a significant part of which is the management of global trial master files (TMF), both paper and electronic.

Phlexglobal’s former financial director, Stella Donoghue, will assume the role of managing director and Karen Redding will remain as global business development manager.

They will be joined by technical director, John Lazenby and Sarah Tucker, who has been internally appointed as director of eTMF operations.

Phlexglobal is also strengthening its existing management team, by recruiting the former managing director for Wyeth Laboratories (UK and Ireland), Kevin James, as its new chairman.

James said the eTMF uptake will follow that trend set by electronic data capture (EDC), which is now used for the majority of clinical trials.

Phlexglobal’s second US office in Philadelphia, which is going to be opened in a month, coupled with the MBO is expected to provide a valuable platform for the company to move into new markets including Asia-Pacific, while still maintaining its strong presence in the UK and North America.